Here’s how Jaguar Health, Inc. (JAGX) plummeted in the premarket today


Jaguar Health, Inc. (NASDAQ:JAGX) shares dipped -22.63% to $0.82 in the premarket session ‎after the report that the Firm has reached an agreement with a secured lender a non-‎dilutive royalty funding deal.In the agreement, Jaguar will sell a royalty interest to the ‎Lender for an aggregate purchase price of $6 million, entitling the Lender to obtain 2.0x the ‎royalty purchase price of Mytesi and Lechlemer’s potential royalties and others upwards of ‎‎$6 million.‎

Get the hottest stocks to trade every day ‎before the market opens 100% ‎free. Click here now. 

‎Jaguar plans to use the proceeds to finance the Company’s research pipeline-related ‎regulatory operations, including ongoing funding patient registration for the cornerstone ‎phase 3 trial of crofelemer for diarrhea prophylaxis in adult cancer patients undergoing ‎targeted therapy launched last October by the wholly-owned subsidiary of the Company, ‎Napo Pharmaceuticals, Inc. (Napo). This $6 million royalty funding deal follows an earlier $6 ‎million royalty transaction with a Lender partner concluded in October 2020.‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

Moreover, we reported yesterday that Jaguar Health (JAGX) announced the results of the ‎special meeting of Jaguar stockholders ‎held on December 9, 2020. ‎


Please enter your comment!
Please enter your name here